Arovella Newsletter August 2024
Welcome to this instalment of Arovella’s newsletter. We have had a productive few months, and the foundations have been firmly laid to take ALA-101 into first-in-human clinical trials. You may recall that earlier in the year we completed a Placement to raise $12.5 million. The level of interest was exceptional, and we are delighted that we have continued to trade well above the issue price since the issuance. More importantly, we have already put some of the funds to good use, completing the process development work for ALA-101, which now means we have a manufacturing process that is capable of being scaled-up and is semi-automated.
Highlights:
Completed scale-up of its CAR-iNKT manufacturing process to enable GMP manufacturing of ALA-101 for phase 1 trials.
Held a pre-IND meeting with FDA and received positive feedback regarding the development path for ALA-101.
Welcomed new talent to the Arovella team.
Presented at the Allogeneic Cell Therapies conference in Boston.
